Market research
002620.KO Jeil Pharma Holdings Inc
KO KRW Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 111B
- P/E ratio
- 13.18
- Analyst target
- Not available
- Dividend yield
- 1.0%
- Beta
- 0.45
Profile
Instrument facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- KR7002620003
- Market cap
- 111B
- P/E ratio
- 13.18
- Analyst target
- Not available
- Dividend yield
- 1.0%
- Beta
- 0.45
About
About Jeil Pharma Holdings Inc
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Research context
Jeil Pharma Holdings Inc appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 002620.KO discussion.
5 years, 6 months ago
Jeil Pharma Holdings Inc is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 95.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.4.
Jeil Pharma Holdings Inc's total revenue rose by 6.2% to $190B since the same quarter in the previous year.
Its net income has increased by 102.7% to $3B since the same quarter in the previous year.
Finally, its free cash flow fell by 202.5% to $-2B since the same quarter in the previous year.
Based on the above factors, Jeil Pharma Holdings Inc gets an overall score of 4/5.